We scan new podcasts and send you the top 5 insights daily.
Although investigational BTK degraders demonstrate 22 to 24 months of median progression-free survival in refractory CLL, continuous frontline application risks selecting for the A428D mutation. This recurrent mutation renders CLL cells resistant to all BTK-targeting agents, prompting caution against continuous frontline use over time-limited combinations.
The linear progression through generations of BTK inhibitors may be a flawed strategy, as indefinite kinase blocking is unsustainable. The future likely lies in BTK degraders, a new drug class that eliminates the target protein entirely, offering a novel approach to overcoming resistance instead of just inhibiting the protein.
Non-covalent BTK inhibitors like pirtobrutinib are currently approved for use after covalent BTK inhibitors fail. Moving them to the frontline setting, as studied in BRUIN-313, disrupts the established treatment pathway and creates uncertainty for managing relapsed disease, as the standard 'next step' is removed.
BTK degraders work despite most kinase inhibitor resistance mutations. However, resistance to degraders themselves alters the BTK binding pocket so significantly that subsequent targeting with any BTK kinase inhibitor is unlikely to be effective, positioning them as a potential end-of-line therapy.
Clinical data suggests that using time-limited venetoclax-BTK inhibitor combinations in the frontline setting mitigates the emergence of BCL2 or BTK resistance mutations. This provides a key biological rationale supporting this approach, as it preserves future treatment options and allows for successful retreatment.
The FLAIR trial provided the first clinical evidence that a time-limited combination of ibrutinib and venetoclax prevents the development of BTK resistance mutations. These mutations were observed in patients receiving continuous single-agent BTK inhibitor therapy, supporting a key theoretical advantage of time-limited combination approaches.
A forward-thinking strategy for managing patients on continuous BTK inhibitors involves screening for emerging resistance mutations. These mutations have a lead time of about nine months before clinical resistance develops. This provides a window to switch therapies proactively, rather than waiting for clinical progression.
Using the non-covalent BTK inhibitor pirtobrutinib in the frontline setting poses a strategic risk. It can induce resistance mutations (e.g., T474I) that confer cross-resistance to both covalent and non-covalent BTK inhibitors, potentially eliminating an entire class of drugs for future use.
Despite demonstrating favorable cardiac tolerability with low rates of atrial fibrillation, non-covalent pirtobrutinib poses unresolved sequencing concerns. Clinicians worry that frontline pirtobrutinib could induce cross-resistance preventing subsequent covalent BTK efficacy, leading them to restrict upfront use strictly to patients with substantial cardiovascular comorbidities.
Unlike continuous BTK inhibitor therapy, using a BTK inhibitor as part of a time-limited combination regimen does not appear to select for resistance mutations. This crucial distinction means that a BTK inhibitor could potentially be used again effectively as a subsequent line of therapy if the patient relapses.
Although BTK degraders show exceptional activity in heavily pretreated CLL, using them as continuous frontline monotherapy raises serious sequencing concerns. Early mechanistic data reveal the A428D mutation can emerge, which confers broad cross-resistance to covalent, non-covalent, and degradation-based BTK-targeting therapies.